Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRACTALL: Anti-CCR9 CAR T Cells in T-ALL and T-LBL
NCT07300683Phase 1Recruiting
- Sponsor
- University College London
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CCR9 CAR-T in acute lymphoblastic leukemia (ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by University College London. Primary endpoints: Feasibility of generation of CARCCR9 T cells at 2 years and Incidence of treatment-related adverse events at 28 days. Started Nov 2025; status: recruiting.
02
Drugs
anti-CCR9 CAR-T
03
Conditions
acute lymphoblastic leukemia (ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT07300683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300683.